Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Hepatocellular Carcinoma: A Review of Emerging Applications for Locoregional Therapy
Open Access
- 12 August 2025
- journal article
- review article
- Published by MDPI AG in Bioengineering
- Vol. 12 (8) , 870
Abstract
Quantitative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is emerging as a valuable tool for assessing tumor and parenchymal perfusion in the liver, playing a developing role in locoregional therapies (LRTs) for hepatocellular carcinoma (HCC). This review explores the conceptual underpinnings and early investigational stages of DCE-MRI for LRTs, including thermal ablation, transarterial chemoembolization (TACE), and transarterial radioembolization (TARE). Preclinical and early-phase studies suggest that DCE-MRI may offer valuable insights into HCC tumor microvasculature, treatment response, and therapy planning. In thermal ablation therapies, DCE-MRI provides a quantitative measurement of tumor microvasculature and perfusion, which can guide more effective energy delivery and estimation of ablation margins. For TACE, DCE-MRI parameters are proving their potential to describe treatment efficacy and predict recurrence, especially when combined with adjuvant therapies. In 90Y TARE, DCE-MRI shows promise for refining dosimetry planning by mapping tumor blood flow to improve microsphere distribution. However, despite these promising applications, there remains a profound gap between early investigational studies and clinical translation. Current quantitative DCE-MRI research is largely confined to phantom models and initial feasibility assessments, with robust retrospective data notably lacking and prospective clinical trials yet to be initiated. With continued development, DCE-MRI has the potential to personalize LRT treatment approaches and serve as an important tool to enhance patient outcomes for HCC.Keywords
Funding Information
- RSNA Research Scholar (RSCH2303, NIH UL1TR001881)
- UCLA Department of Radiological Sciences Exploratory (RSCH2303, NIH UL1TR001881)
This publication has 66 references indexed in Scilit:
- Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY StudyHepatology, 2021
- DCE‐MRI protocol for constraining absolute pharmacokinetic modeling errors within specific accuracy limitsMedical Physics, 2019
- Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE‐MRI derived biomarkers in multicenter oncology trialsJournal of Magnetic Resonance Imaging, 2018
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver DiseasesHepatology, 2018
- Unresectable Solitary Hepatocellular Carcinoma Not Amenable to Radiofrequency Ablation: Multicenter Radiology-Pathology Correlation and Survival of Radiation SegmentectomyHepatology, 2014
- DCE‐MRI of the liver: Effect of linear and nonlinear conversions on hepatic perfusion quantification and reproducibilityJournal of Magnetic Resonance Imaging, 2013
- Tumor response assessments with diffusion and perfusion MRIJournal of Magnetic Resonance Imaging, 2012
- Pharmacokinetic parameters from 3‐Tesla DCE‐MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasisInternational Journal of Cancer, 2011
- Estimating kinetic parameters from dynamic contrast-enhanced t1-weighted MRI of a diffusable tracer: Standardized quantities and symbolsJournal of Magnetic Resonance Imaging, 1999
- Modeling tracer kinetics in dynamic Gd‐DTPA MR imagingJournal of Magnetic Resonance Imaging, 1997